Bliss GVS Pharma Intrinsic Value
Bliss GVS Pharma (BLISSGVS) median intrinsic value is ₹984.10 from 10 valuation models (range ₹157–₹1309), vs current price ₹523.55 — +88.0% upside (Trading Below Calculated Value), margin of safety 46.8%. Analyse BLISSGVS institutional holdings to track promoter, FII and institutional holdings.
BLISSGVS Valuation Methods Summary — DCF, Graham Number & P/E
Bliss GVS Pharma intrinsic value across 10 models vs current price ₹523.55 — upside/downside and value range per method. Read BLISSGVS dividend growth for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹283.36 | ₹226.69 - ₹340.03 | -45.9% | EPS: ₹12.88, Sector P/E: 22x |
| Book Value Method | asset | ₹1308.88 | ₹1177.99 - ₹1439.77 | +150.0% | Book Value/Share: ₹1120.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1047.10 | ₹942.39 - ₹1151.81 | +100.0% | Revenue/Share: ₹974.55, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1047.10 | ₹942.39 - ₹1151.81 | +100.0% | EBITDA: ₹224.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹984.10 | ₹787.28 - ₹1180.92 | +88.0% | CF Growth: 0.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹157.06 | ₹141.35 - ₹172.77 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹199.00 | ₹179.10 - ₹218.90 | -62.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1047.10 | ₹942.39 - ₹1151.81 | +100.0% | ROE: 12.0%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹569.72 | ₹512.75 - ₹626.69 | +8.8% | EPS: ₹12.88, BVPS: ₹1120.00 |
| Dividend Yield Method | dividend | ₹157.06 | ₹141.35 - ₹172.77 | -70.0% | DPS: ₹0.50, Target Yield: 2.5% |
BLISSGVS Intrinsic Value vs Market Price — All Valuation Models
Bliss GVS Pharma fair value range ₹157–₹1309 vs current market price ₹523.55 across 10 valuation models. For current market price and key ratios, visit BLISSGVS stock price BSE.
BLISSGVS Intrinsic Value Analysis — Undervalued or Overvalued?
Bliss GVS Pharma median intrinsic value ₹984.10, current price ₹523.55 — Trading Below Calculated Value by 88.0%, margin of safety 46.8%.
What is the intrinsic value of BLISSGVS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Bliss GVS Pharma (BLISSGVS) is ₹984.10 (median value). With the current market price of ₹523.55, this represents a +88.0% variance from our estimated fair value.
The valuation range spans from ₹157.06 to ₹1308.88, indicating ₹157.06 - ₹1308.88.
Is BLISSGVS undervalued or overvalued?
Based on our multi-method analysis, Bliss GVS Pharma (BLISSGVS) appears to be trading below calculated value by approximately 88.0%.
BLISSGVS Financial Health — Key Ratios vs Industry Benchmarks
Bliss GVS Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 37.84 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 12.0% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.72x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
BLISSGVS Cash Flow Quality — Operating & Free Cash Flow
Bliss GVS Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹139 Cr | ₹120 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹106 Cr | ₹68 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹103 Cr | ₹62 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹34 Cr | ₹31 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹136 Cr | ₹85 Cr | Positive Free Cash Flow | 8/10 |